Kairos Pharma Reports Promising Phase 2 Results for ENV105 in Prostate Cancer Treatment

Kairos Pharma Ltd. (NYSE American: KAPA) announced positive interim efficacy data from its ongoing Phase 2 trial of ENV105 (carotuximab) in metastatic castration-resistant prostate cancer, showing promising results that could impact treatment approaches for this challenging cancer type. Among eight evaluable patients, the ENV105 and apalutamide combination achieved median progression-free survival of more than 13 months, significantly exceeding the trial's target of a 45% improvement compared with the standard 3.7 months for second- or third-line hormone therapy.

The clinical data revealed that five patients remain on treatment, with seven of nine showing declines in prostate-specific antigen levels, indicating potential therapeutic benefit. The treatment combination was well tolerated with no dose-limiting toxicities observed, suggesting a favorable safety profile for continued development. These findings are particularly significant given the high unmet medical need in metastatic castration-resistant prostate cancer, where treatment resistance often develops against standard therapies.

ENV105 represents an innovative approach to cancer treatment as an antibody targeting CD105, a protein identified as a key driver of resistance to various cancer treatments. According to company information available at https://ibn.fm/KAPA, elevation of CD105 in response to standard therapy results in resistance and disease relapse, making ENV105's mechanism of action particularly relevant for addressing treatment-resistant cancers. The drug aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.

The positive interim results position ENV105 as a potential combination therapy that could enhance the efficacy of existing prostate cancer treatments. The extended progression-free survival observed in this trial suggests that targeting CD105 may effectively overcome resistance mechanisms that typically limit treatment duration and effectiveness in advanced prostate cancer patients. These findings could have broader implications for cancer treatment strategies beyond prostate cancer, as CD105-mediated resistance represents a common challenge across multiple oncology indications.

Kairos Pharma's ongoing clinical development program includes additional trials evaluating ENV105's potential, including a Phase 1 trial for lung cancer. The company's focus on utilizing structural biology to overcome drug resistance and immune suppression in cancer aligns with growing recognition within the oncology field that combination approaches targeting resistance mechanisms may be necessary to achieve meaningful improvements in cancer outcomes. The full press release detailing these findings can be accessed at https://ibn.fm/BSLuY, providing comprehensive data for the medical and investment communities.